Today is September 25, 2024. All times in Eastern Daylight Time.
Porter Airlines remporte le prix de la meilleure classe économique de USA Today
09/25/2024 - 12:15 PM
BUSINESS WIRE
Porter Airlines wins USA Today Best Economy Class
09/25/2024 - 12:14 PM
BUSINESS WIRE
Global Road Construction Project Insights: Q2 2024 Report - Track $3.44 Trillion in the Pipeline with North East Asia Leading with Projects Worth $922.5 Billion - ResearchAndMarkets.com
09/25/2024 - 12:14 PM
BUSINESS WIRE
Riassunto: Fujirebio presenta alla FDA la richiesta per l'approvazione del test diagnostico in vitro Lumipulse® G pTau 217/β-amiloide 1-42 plasmatico come ausilio per l'identificazione dei pazienti con patologia amiloide associata alla malattia di Alzheimer
09/25/2024 - 12:13 PM
BUSINESS WIRE
Fujirebio presenta ante la FDA la solicitud de registro para la prueba de diagnóstico in vitro Lumipulse® G pTau 217/β-Amiloide 1-42 Plasma Ratio como ayuda para identificar pacientes con patología amiloide asociada a la enfermedad de Alzheimer
09/25/2024 - 12:13 PM
BUSINESS WIRE
Samenvatting: Fujirebio dient reglementaire registratie bij FDA in voor de in-vitro diagnosetest Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio als hulpmiddel om patiënten te identificeren met amyloïdpathologie die verband houdt met de ziekte van Alzheimer
09/25/2024 - 12:13 PM
BUSINESS WIRE
Xsolla任命Zoran Vasiljev为全球战略合作伙伴关系高级副总裁
09/25/2024 - 12:13 PM
BUSINESS WIRE
Fujirebio reicht bei der FDA einen Zulassungsantrag für den Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro-Diagnosetest ein, um Patienten mit einer Amyloid-Pathologie im Zusammenhang mit der Alzheimer-Krankheit zu identifizieren
09/25/2024 - 12:12 PM
BUSINESS WIRE
Fujirebio为Lumipulse® G pTau 217/β-淀粉样蛋白1-42血浆比值体外诊断测试提交FDA监管文件,该测试有助于识别与阿尔茨海默病相关的淀粉样蛋白病变患者
09/25/2024 - 12:12 PM
BUSINESS WIRE
Fujirebio為Lumipulse® G pTau 217/β-澱粉樣蛋白1-42血漿比值體外診斷測試遞交FDA監管文件,該測試有助於辨識與阿茲海默症相關的澱粉樣蛋白病變病患
09/25/2024 - 12:12 PM
BUSINESS WIRE
1
2
3
4
5
6
7
8
9
10
11
...
1569
« Previous
Next »